Online citations, reference lists, and bibliographies.
← Back to Search

A Review On The Strategies For Oral Delivery Of Proteins And Peptides And Their Clinical Perspectives

Abdul Muheem, F. Shakeel, M. A. Jahangir, M. Anwar, N. Mallick, G. Jain, M. Warsi, F. Ahmad
Published 2016 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
In the modern world, a number of therapeutic proteins such as vaccines, antigens, and hormones are being developed utilizing different sophisticated biotechnological techniques like recombinant DNA technology and protein purification. However, the major glitches in the optimal utilization of therapeutic proteins and peptides by the oral route are their extensive hepatic first-pass metabolism, degradation in the gastrointestinal tract (presence of enzymes and pH-dependent factors), large molecular size and poor permeation. These problems can be overcome by adopting techniques such as chemical transformation of protein structures, enzyme inhibitors, mucoadhesive polymers and permeation enhancers. Being invasive, parenteral route is inconvenient for the administration of protein and peptides, several research endeavors have been undertaken to formulate a better delivery system for proteins and peptides with major emphasis on non-invasive routes such as oral, transdermal, vaginal, rectal, pulmonary and intrauterine. This review article emphasizes on the recent advancements made in the delivery of protein and peptides by a non-invasive (peroral) route into the body.
This paper references
10.1016/S1359-6446(05)03536-1
Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting.
D. Brayden (2005)
Protein and peptide drug delivery: oral approaches. Ind
J Shaji (2008)
10.3109/03639048209022119
The Production and Evaluation of Orally Administered Insulin Nanoparticles
R. Oppenheim (1982)
10.3892/IJO.23.4.1095
The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review).
M. V. Cronauer (2003)
10.1023/A:1010936227570
Oral Delivery of Biologically Active Parathyroid Hormone
A. Leone-Bay (2004)
10.1016/J.MATBIO.2005.03.007
Matrix metalloproteinase expression and function during fin regeneration in zebrafish: analysis of MT1-MMP, MMP2 and TIMP2.
Shan Bai (2005)
10.1016/S0142-9612(00)00134-4
Enhancing effect of chitosan on peptide drug delivery across buccal mucosa.
S. Şenel (2000)
10.1016/S0142-9612(00)00039-9
Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro.
M. Marschütz (2000)
10.2165/00063030-200519030-00003
Oral Delivery of Peptide Drugs
J. Hamman (2012)
10.1677/JOE.0.1620361
Transport of IGF-I across epithelial cell monolayers.
S. Bastian (1999)
10.1016/J.JCONREL.2004.07.030
Transmucosal macromolecular drug delivery.
C. Prego (2005)
10.3109/10717544.2013.819611
Oral delivery of therapeutic proteins and peptides: a review on recent developments
S. Gupta (2013)
The effect of protein
R. A. Judge (1998)
10.1016/J.EJPS.2005.04.015
Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium.
A. des Rieux (2005)
Oral delivery of vaccines using polymerized liposomes
R. C. Oppenheim
10.1002/JPS.10573
Biodegradable nanoparticles containing protein‐fatty acid complexes for oral delivery of salmon calcitonin
H. Yoo (2004)
Comparison of monomeric
C. J. Lim (2005)
10.1016/j.addr.2013.04.006
Oral delivery of proteins by biodegradable nanoparticles.
S. Bakhru (2013)
10.3109/10717549509031355
Oral colon-specific drug delivery: a review
G. Mooter (1995)
Oral insulin – a review
K. Anand (2010)
10.1016/J.ADDR.2007.08.019
Current challenges in non-invasive insulin delivery systems: a comparative review.
E. Khafagy (2007)
10.2337/DIACARE.28.5.1068
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
J. Skyler (2005)
10.1038/386410A0
Biologically erodable microspheres as potential oral drug delivery systems
E. Mathiowitz (1997)
10.1016/j.ijpharm.2013.02.030
Approaches for enhancing oral bioavailability of peptides and proteins.
J. Renukuntla (2013)
10.1016/j.ejpb.2009.06.004
Formulation and characterization of an oily-based system for oral delivery of insulin.
A. Elsayed (2009)
10.1023/A:1015921101465
Absorption of Polyethylene Glycols 600 Through 2000: The Molecular Weight Dependence of Gastrointestinal and Nasal Absorption
M. Donovan (2004)
10.1016/J.EJPS.2005.03.003
Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method.
Shmuel Hess (2005)
The androgen
A. De la Taille (2003)
10.1023/A:1012108118670
Novel Bioadhesive Chitosan-EDTA Conjugate Protects Leucine Enkephalin from Degradation by Aminopeptidase N
A. Bernkop-Schnürch (2004)
10.2174/138161209788682523
Current prodrug design for drug discovery.
Pei-Wen Hsieh (2009)
10.1007/s00125-001-0751-z
Self-assembled “nanocubicle” as a carrier for peroral insulin delivery
H. Chung (2001)
10.1016/J.REACTFUNCTPOLYM.2010.10.002
Oral protein delivery: Current status and future prospect
K. Park (2011)
10.1016/J.EJPB.2005.04.006
Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice.
Monjed Shakweh (2005)
10.1016/S1359-6446(03)02692-8
Oral peptide and protein delivery: unfulfilled promises?
W. Shen (2003)
10.1038/nrd1067
Challenges for the oral delivery of macromolecules
M. Goldberg (2003)
MMP2 and TIMP2
S. H. Bakhru (2013)
The Buccal Delivery of Insulin
10.1016/S0167-7799(97)01070-6
Towards an oral influenza vaccine.
P. J. Sizer (1997)
10.1016/J.EJPS.2004.03.015
Development and in vivo evaluation of an oral insulin-PEG delivery system.
P. Calceti (2004)
10.1021/BC050322Y
Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
A. Basu (2006)
10.1016/j.jconrel.2008.10.012
Development of a Gas Empowered Drug Delivery system for peptide delivery in the small intestine.
A. Sadeghi (2009)
Develop - ment of acrylic - based copolymers for oral insulin delivery
J. M. Gamboa (2008)
Methodo - logical and cellular aspects that govern the internalization mechanisms of arginine - rich cell - penetrating peptides
K. Noriyasu
10.4103/0250-474X.42967
Protein and Peptide Drug Delivery: Oral Approaches
J. Shaji (2008)
10.1111/j.2042-7158.1997.tb06773.x
Degradation of Insulin and Calcitonin and Their Protection by Various Protease Inhibitors in Rat Caecal Contents: Implications in Peptide Delivery to the Colon
H. Tozaki (1997)
In vitro and in vivo models for
J. M. Gamboa (2013)
Current Status of the Oral Delivery of Insulin
V. Agarwal (2001)
10.1023/A:1016073416332
pH-Sensitive Nanoparticles: An Effective Means to Improve the Oral Delivery of HIV-1 Protease Inhibitors in Dogs
J. Leroux (2004)
10.1016/0168-3659(92)90016-K
Niosomes for oral delivery of peptide drugs
H. Yoshida (1992)
10.1080/026520499289013
Calcium alginate microparticles for oral administration: I: Effect of sodium alginate type on drug release and drug entrapment efficiency.
S. Takka (1999)
10.1016/j.ijpharm.2012.03.056
Oral delivery of therapeutic protein/peptide for diabetes--future perspectives.
M. Rekha (2013)
10.2174/092986710793205426
Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
S. Jana (2010)
Drug delivery in diabetes : oral - lyn needle - free buccal delivery of insulin
J. Blanchette
10.1016/J.BIOPHA.2004.01.006
Principles of transmucosal delivery of therapeutic agents.
J. Blanchette (2004)
10.5040/9781408185094.00000006
The effect of the
C. McGrath (1997)
10.1615/CRITREVTHERDRUGCARRIERSYST.V20.I23.30
Emerging trends in oral delivery of peptide and protein drugs.
R. Mahato (2003)
10.2165/00003088-199222010-00001
Oral Delivery of Vaccines
D. O'hagan (1992)
10.1002/cmdc.200700239
Vitamin B12 as a Carrier for the Oral Delivery of Insulin
Amanda K. Petrus (2007)
10.1007/s11095-005-6137-z
Region-Dependent Role of the Mucous/Glycocalyx Layers in Insulin Permeation Across Rat Small Intestinal Membrane
Y. Aoki (2005)
Sandimmun neoral pharmacokinetics: impact of the new oral formulation.
D. Holt (1995)
10.4155/TDE.11.132
Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET).
E. Walsh (2011)
New development in insulin delivery
M. Kidron (2004)
10.1016/j.jconrel.2010.02.001
A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa.
Abdallah Makhlof (2011)
10.1074/jbc.271.30.18188
Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent*
D. Derossi (1996)
10.4155/TDE.11.114
Oral peptide delivery: prioritizing the leading technologies.
D. Brayden (2011)
10.1016/S0928-0987(03)00134-9
Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs.
G. Dollo (2003)
10.1016/0167-7799(96)10031-7
Novel crystalline catalysts
A. Margolin (1996)
Oral peptide delivery: prioritizing
D. J. 142–151. Brayden (2011)
10.1172/JCI119271
Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model.
A. Fasano (1997)
10.1016/S0169-409X(00)00119-8
Design of nanoparticles composed of graft copolymers for oral peptide delivery.
S. Sakuma (2001)
10.1021/bi973043
An ester bond linking a fragment of a serine proteinase to its serpin inhibitor.
R. Egelund (1998)
10.1016/J.ADDR.2007.10.006
Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides.
I. Nakase (2008)
Pharmaceutical Combinations And Related Methods Of Delivery. (LandoAndAnastasi), USP Application 01056275A1
P. Salama (2010)
10.1016/0928-0987(95)00042-9
MUCOADHESIVE POLYMERS IN PERORAL PEPTIDE DRUG DELIVERY. I. INFLUENCE OF MUCOADHESIVE EXCIPIENTS ON THE PROTEOLYTIC ACTIVITY OF INTESTINAL ENZYMES
H. L. Luessen (1996)
Chitosan - based gastrointestinal delivery system
S. Hess (2003)
Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy non-diabetic subjects
E. Wajberg (2004)
10.1021/CR000700M
Peroral route: an opportunity for protein and peptide drug delivery.
A. Sood (2001)
10.1038/nrd2399
Protein therapeutics: a summary and pharmacological classification
B. Leader (2008)
Biologically erodible microspheres
D.E (1997)
10.1080/026520499289022
Calcium alginate microparticles for oral administration: II. Effect of formulation factors on drug release and drug entrapment efficiency.
F. Acartürk (1999)
10.1111/j.1464-5491.2004.01160.x
A novel per‐oral insulin formulation: proof of concept study in non‐diabetic subjects
M. Kidron (2004)
10.1016/j.jconrel.2010.10.029
Release and bioactivity of PACA nanoparticles containing D-Lys⁶-GnRH for brushtail possum fertility control.
Alexandra P Kafka (2011)
Comparative bioavailability of two brands of cyclosporin
A. Sachdeva (1997)
10.1016/J.TIPS.2004.05.006
Techniques: new approaches to the delivery of biopharmaceuticals.
G. Orive (2004)
10.1111/j.1463-1326.2009.01150.x
Oral insulin – a review of current status
H. Iyer (2010)
10.4103/0975-7406.76478
Mucoadhesive drug delivery systems
Rahamatullah Shaikh (2011)
on additional clinical data from oral cyclosporine trial (Novartis)
10.2174/1389200211309010004
Models to predict intestinal absorption of therapeutic peptides and proteins.
Filipa Antunes (2013)
Biologically erodible microspheres as potential oral drug delivery systems
T. Mizuma
Sandimmune nerol pharmacokinetics: impact
K. Kutz (1995)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I2.20
Oral delivery of proteins: progress and prognostication.
R. Shah (2002)
10.1016/j.addr.2009.09.006
Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic.
S. Maher (2009)
10.1177/0091270010372625
Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials
M. Karsdal (2011)
10.1016/j.addr.2013.01.003
In vitro and in vivo models for the study of oral delivery of nanoparticles.
J. Gamboa (2013)
10.2337/diab.37.2.246
New Approach for Oral Administration of Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier
C. Damgé (1988)
Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin.
Hyuk Sang Yoo (2004)
A Five Period, Open Label, Placebo Controlled
P. Kumar (2009)
Comparative bioavailability of two brands of cyclosporine
A. Sachdeva (1997)
10.1016/j.ijpharm.2012.05.033
Targeted lipid based drug conjugates: a novel strategy for drug delivery.
A. D. Vadlapudi (2012)
10.1002/(SICI)1097-0290(19980920)59:6<776::AID-BIT14>3.0.CO;2-3
The effect of protein impurities on lysozyme crystal growth.
R. Judge (1998)
10.1007/978-1-60761-609-2_11
Polymeric nanoparticles for drug delivery.
J. M. Chan (2010)
10.3109/10409239209082559
Mucin-type glycoproteins.
G. Strous (1992)
10.1016/J.ADDR.2006.01.003
Tight junction modulation and its relationship to drug delivery.
N. Salama (2006)
A 2-week randomized, active comparator study of two HDV-Insulin routes (SC and oral) and SC human insulin in patients with type 1 diabetes mellitus
S. Schwartz (2008)
10.1016/J.ADDR.2005.07.002
Thiomers: a new generation of mucoadhesive polymers.
A. Bernkop-Schnürch (2005)
10.1016/J.LFS.2004.05.027
The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer.
Z. Değim (2004)
10.1007/978-3-319-41818-6
Protein Therapeutics
Z. Sauna (2017)
10.1615/CRITREVTHERDRUGCARRIERSYST.V12.I2-3.10
Approaches and opportunities in colon-specific drug delivery.
A. Rubinstein (1995)
10.1002/(SICI)1520-6017(200004)89:4<556::AID-JPS13>3.0.CO;2-C
Evaluation of skin damage caused by percutaneous absorption enhancers using fractal analysis.
Y. Obata (2000)
10.1042/BJ20050401
Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules.
C. de Coupade (2005)
10.3390/biom2020187
Cell Penetrating Peptides in the Delivery of Biopharmaceuticals
Were LL Munyendo (2012)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
Sandimmune nerol pharmacokinetics : impact of new oral formulation
P. W. Hsieh (1995)
10.1016/S0939-6411(03)00145-0
Development of acrylic-based copolymers for oral insulin delivery.
Aaron C Foss (2004)
10.1016/j.amjmed.2009.12.007
Incretin-based therapies: review of current clinical trial data.
A. Peters (2010)
Comparative bioavailability of two brands of cyclosporine. Ind
A Sachdeva (1997)
Oral peptide drug
ジリガン,ジェイムズ・ピー (1997)
10.1016/S0378-5173(02)00486-6
Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo.
Yan Pan (2002)
Emerging trends in oral delivery of peptide and proteins
S. Maher (2009)
10.1023/A:1018968611962
Effects of Various Protease Inhibitors on the Intestinal Absorption and Degradation of Insulin in Rats
A. Yamamoto (2004)
10.1016/J.DRUDIS.2006.08.005
Is the oral route possible for peptide and protein drug delivery?
M. Morishita (2006)
Source Apollo life sciences
(2010)
10.1007/s00125-004-1658-2
A new drug carrier, Nα-deoxycholyl-l-lysyl-methylester, for enhancing insulin absorption in the intestine
S. Lee (2004)
10.1016/J.JCONREL.2005.05.001
Comparison of monomeric and oligomeric transferrin as potential carrier in oral delivery of protein drugs.
Ching J Lim (2005)
Novel human-derived cell-penetrating
E Tasciotti (2005)
10.1016/S1043-6618(03)00158-0
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.
M. Varma (2003)
10.1590/S1984-82502010000100002
Mucoadhesive drug delivery systems
F. Carvalho (2010)
10.2337/DIACARE.27.12.2868
Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.
E. Wajcberg (2004)
10.1016/J.ADDR.2005.07.003
The use of mucoadhesive polymers in buccal drug delivery.
Nazila Salamat-Miller (2005)
10.1016/S0168-3659(99)00035-8
Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement.
S. J. Wu (1999)
10.1016/j.addr.2012.12.001
Advanced drug delivery: perspectives and prospects. Preface.
V. Lee (2013)
10.1021/JS950507L
Improvement of intestinal absorption of leucine enkephalin by sugar coupling and peptidase inhibitors.
T. Mizuma (1996)
insulin absorption in the intestine
V. M. Leitner (2003)
10.1016/0168-3659(91)90044-E
Controlled release by using poly(methacrylic acid-g-ethylene glycol) hydrogels
N. Peppas (1991)
Drug delivery and targeting.
R. Langer (1998)
10.1016/S0169-409X(98)00040-4
Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract.
Ponchel (1998)
Novel bioadhe
A. Bernkop-Schnurch (1997)
10.1016/J.ADDR.2004.10.010
Cell-penetrating peptides: mechanism and kinetics of cargo delivery.
M. Zorko (2005)
10.1080/10611860701349141
Design and evaluation of a chitosan–aprotinin conjugate for the peroral delivery of therapeutic peptides and proteins susceptible to enzymatic degradation
M. Werle (2007)
10.1016/S0168-3659(03)00126-3
Chitosan-based gastrointestinal delivery systems.
Radi Hejazi (2003)
Pglycoprotein inhibitors and their screening: a perspective from bioavailability
M.V.S. Varma (2003)
10.2337/DIACARE.26.2.421
Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
M. Kipnes (2003)
10.1089/152091502760306544
Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.
S. Clement (2002)
10.1023/A:1016268311867
Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects
P. Constantinides (2004)
10.1021/MA970399K
Analysis of the complexation/decomplexation phenomena in graft copolymer networks
A. Lowman (1997)
Cell penetrating peptides in the delivery
J. Zhou (2012)
Merrion pharmaceuticals
S Frost
A novel per-oral insulin
M Goldberg (2004)
10.1080/10717540500313109
Lecithin-Based Microemulsion of a Peptide for Oral Administration: Preparation, Characterization, and Physical Stability of the Formulation
A. Cilek (2006)
10.1016/S0378-5173(02)00674-9
Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (S/O/W) emulsion.
Eiichi Toorisaka (2003)
Lessons learned from the development
M. R. John (2011)
10.1111/cbdd.12055
The Future of Peptide‐based Drugs
D. Craik (2013)
10.1016/S0378-5173(99)00322-1
Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue.
G. M. Mlynek (2000)
10.1081/DDC-120018199
New Developments in Insulin Delivery
N. Ghilzai (2003)
Oral protein delivery: current
K. Park (2011)
Absorption Of Orally Ingested Insulin In Human Type 1 Diabetic Subjects: Proof Of Concept Study
C. D. Whitelaw (2005)
10.1038/aja.2008.14
The androgen receptor in hormone-refractory prostate cancer.
H. Mao (2009)
10.1016/S0168-3659(99)00247-3
Nanosphere based oral insulin delivery.
G. Carino (2000)
10.1021/BI973043+
An ester bond linking a fragment of a serine proteinase to its serpin inhibitor.
Rikke Egelund (1998)
Oral delivery of biologically active
M Carozza (2001)
Mucoadhesive polymers in peroral
A.G (1996)
10.4155/tde.12.164
Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
N. Kamei (2013)
10.1016/S0928-0987(97)10019-7
Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight.
G. Camenisch (1998)
10.1080/10611860410001693760
Use of Targeting Agents to Increase Uptake and Localization of Drugs to the Intestinal Epithelium
G. J. Russell-Jones (2004)
10.1016/S0939-6411(03)00061-4
Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins.
V. Leitner (2003)
10.1016/S0169-409X(96)00434-6
In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement
E. Lecluyse (1997)
10.1016/j.actbio.2009.01.017
Novel iron-polysaccharide multilayered microcapsules for controlled insulin release.
J. Zheng (2009)



This paper is referenced by
10.1016/j.jpba.2018.07.009
A liquid chromatography high‐resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides
S. Esposito (2018)
Design and synthesis of selective MMP-9 inhibitors for the treatment of epilepsy
Alexandra Bertran Junqué (2018)
10.2174/1566524019666191010095522
A Brief Overview of the Oral Delivery of Insulin as an Alternative to the Parenteral Delivery.
A. Macedo (2020)
10.1080/17474124.2018.1399794
The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery
D. Moss (2018)
10.1080/10717544.2016.1276232
Basic concepts and recent advances in nanogels as carriers for medical applications
I. Neamţu (2017)
10.1080/17425247.2020.1776698
Polyaminoacid-based nanocarriers: a review of the latest candidates for oral drug delivery
Sandra Robla (2020)
I. INTERNSHIP REPORT IN COMMUNITY PHARMACY
Joana Rafaela Sousa Barbosa (2017)
10.1016/J.JFF.2016.01.011
Extraction, identification, and structure–activity relationship of antioxidative and α-amylase inhibitory peptides from cumin seeds (Cuminum cyminum)
Hwee-Leng Siow (2016)
10.1007/s13346-020-00829-x
Overcoming barriers confronting application of protein therapeutics in bone fracture healing
T. Czech (2020)
10.1021/acsomega.0c01792
Enhanced Oral Vaccine Efficacy of Polysaccharide-Coated Calcium Phosphate Nanoparticles
Pei Cao (2020)
10.1016/j.jconrel.2018.08.032
Oral peptide delivery: Translational challenges due to physiological effects
Puneet Tyagi (2018)
10.1016/j.ejpb.2018.04.025
Challenges in the local delivery of peptides and proteins for oral mucositis management
João Campos (2018)
10.1208/s12249-018-0989-0
Daptomycin Proliposomes for Oral Delivery: Formulation, Characterization, and In Vivo Pharmacokinetics
Javier Rueda Arregui (2018)
10.1039/c9mt00131j
Stability of Cu(ii) complexes with FomA protein fragments containing two His residues in the peptide chain.
M. Lesiów (2019)
10.1080/00914037.2015.1038816
A Review: Overview of Novel Polyelectrolyte Complexes as Prospective Drug Bioavailability Enhancers
M. Siyawamwaya (2015)
10.1016/j.addr.2018.01.008
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches☆
A. Mandal (2018)
10.2174/2211738507666190321110721
Nanotechnology in insulin delivery for management of diabetes.
Fatemah Bahman (2019)
Evaluation of the oral delivery of goserelin with Pheroid® technology
L. Erasmus (2017)
10.2174/1567201816666191106102020
Recent avenues in Novel Patient-Friendly Techniques for the Treatment of Diabetes.
S. K. Dubey (2019)
10.1016/j.jconrel.2018.12.017
Alginate/chitosan microparticles for gastric passage and intestinal release of therapeutic protein nanoparticles
Kevin Ling (2019)
10.1002/ADV.22164
Pharmacokinetic evaluation of novel pH‐sensitive poly(2‐methoxyethyl methacrylate‐co‐itaconic acid) microgels in rabbits
Zermina Rashid (2018)
10.3390/pharmaceutics11010036
Intestinal Drug Absorption Enhancement by Aloe vera Gel and Whole Leaf Extract: In Vitro Investigations into the Mechanisms of Action
Anja Haasbroek (2019)
10.1007/978-3-030-35910-2_3
Overview of the Advantages and Disadvantages of Different Mucosal Sites for the Delivery of Nanoparticles
K. Kaneko (2020)
10.2174/1568026619666190304155711
Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors.
P. Jenardhanan (2019)
10.1016/B978-0-323-46143-6.00027-0
Drug delivery: advancements and challenges
Narinder Singh (2017)
10.1080/17425247.2019.1662785
Long-term delivery of protein and peptide therapeutics for cancer therapies
Sadia Sikder (2019)
10.1007/978-3-319-95807-1_24
Ocular Delivery of Peptides and Proteins
R. Dahiya (2018)
DDDT_A_217211 3405..3418
Mohsen Doostmohammadi (2019)
Loading and coating of microcontainers for oral drug delivery
C. Mazzoni (2019)
An ex vivo investigation of the potential drug permeation enhancing effects of selected pepper extracts
V. Niekerk (2019)
10.1002/adfm.202002912
Ionic Liquids and Deep Eutectic Solvents for Enhanced Delivery of Antibodies in the Gastrointestinal Tract
Pavimol Angsantikul (2020)
10.1590/0001-3765202020180609
β-galactosidase Encapsulated in Carrageenan, Pectin and Carrageenan/Pectin: Comparative Study, Stability and Controlled Release.
R. C. Silva (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar